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ABSTRACT 
HAILEY ELISABETH GRISHAM: O-GlcNAc Post Translational Modification of 
Hypoxia-Inducible Factor (HIF) Proteins 
(Under the direction of Dr. Yu-Dong Zhou & Dr. Dale G. Nagle) 
O-linked β-N-acetylglucosamine (O-GlcNAc) post-translational modification (O-
GlcNAcylation), plays a vital role in many metabolic pathways, including those of 
numerous diseases.  New research methods and basic functional roles of O-GlcNAc post-
translational modification on metabolism, human health, and cancer are quickly 
developing, but a vast amount of research remains on the specificity of this pathway 
towards specific proteins.  In this study, T47D breast cancer cells were used as an in vitro 
model to investigate the effects of O-GlcNAc modification on hypoxia-inducible factor 
(HIF) proteins.   
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Chapter 1 
Introduction 
Hailey Grisham 
1.1 O-GlcNAc Background 
 Post translational protein modification (PTM) allows cells to quickly respond to 
internal and external changes by diversifying protein functionality.  Some of the most 
well characterized PTMs include phosphorylation, acetylation, glycosylation, and 
ubiquitination.  While these modification pathways have been extensively studied, a 
number of critical PTMs and their functions are only beginning to be discovered and 
more broadly appreciated (Yang and Qian, 2017).  Discovered in the 1980s, O-linked β-
N-acetylglucosamine (O-GlcNAc) post-translational modification (O-GlcNAcylation) 
plays a vital role in many crucial biological functions.  The extent of these functions is 
only beginning to be uncovered as researchers are looking for new methods of site-
mapping specific O-GlcNAc proteins and discovering new methods to profile these 
proteins (Ma and Hart, 2014). 
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1.2 O-GlcNAcylation and Research Methods 
 Comparable to glycosylation, O-GlcNAcylation attaches O-GlcNAc components 
to serine and threonine residues within proteins of the cytoplasm, mitochondria, and 
nucleus.  The hexosamine biosynthetic pathway (HBP), which metabolizes various 
biological nutrients, creates uridine diphosphate GlcNAc (UDP-GlcNAc) as a substrate to 
be used for O-GlcNAcylation to modify sugars onto the serine and threonine hydroxy 
groups.  Thus, O-GlcNAc works as a stress and nutrient sensor capable of using cellular 
metabolism combined with other PTMs to signal and conduct a vast variety of biological 
processes (Ma and Hart, 2014; Yang and Qian, 2017).   
 The process of  O-GlcNAcylation is controlled by a pair of enzymes, O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA).  These enzymes control the addition and 
removal of O-GlcNAc to and from the amino acid residues, serine and threonine (Ma and 
Hart, 2014).  Though researchers are lacking in knowledge of all of its sequencing, OGT 
is known to be responsible for the transfer of Glc-NAc from UDP-GlcNAc to the amino 
acid residues.  The enzyme OGA has been found in all tissues and is responsible for 
removing Glc-NAc by catalyzing hydrolysis (Vaidyanathan et al., 2014; Yang and Qian, 
2017).  This enzyme pair is cable of recognizing hundreds of protein substrates, but 
researchers continue to search for techniques to determine substrate specificity to OGT 
and OGA (Yang and Qian, 2017). 
 One major goal in building a foundational knowledge on the effects of O-
GlcNAcylation aims to explicitly identify the role of this process on specific proteins.  
Typical methods to prove the presence of O-GlcNAc include Western blot, 
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autoradiography, Edman sequencing, and mass spectrometry (MS).  Because the effects 
of O-GlcNAcylation occur at many substrate sites with differing functions, defining the 
characteristics of each location will help to better understand the role of O-GlcNAc. 
 Combinations of classic research techniques along with more recent research 
methods has continued to expand the number of recognized O-GlcNAcylation sites.  
Western blot, a technique useful for identifying specific proteins, utilizes antibodies 
capable of distinguishing O-GlcNAc properties on proteins.  This technique appears more 
precise than autoradiography, but in order to increase the range of results, multiple 
immunoassays using many antibodies are needed to distinguish O-GlcNAc patterns 
within any given protein sample.  Immunoblotting is often combined with 
immunoprecipitation (IP) to isolate the protein of interest from the rest of the sample.  
While Western blotting and autoradiography may be useful in identifying the presence of 
the O-GlcNAc of proteins, Edman sequencing and MS techniques are strategies useful in 
determining the exact function of specific modification sites.  Edman sequencing has 
been found to be most helpful in differentiating isobaric masses of peptides with O-
GlcNAcylation.  New MS techniques allow researchers to gain a range of information 
about the proteins and peptides of interest.  As the use of this more advanced method 
develops, specified details of O-GlcNAc should become more accessible. 
 Overall, O-GlcNAcylation process is utilized in a vast number of biological 
processes, such as transcription, translation, epigenetics, signaling, and other vital system 
responses.  The relationship of O-GlcNAc with so many fundamental mechanisms creates 
a link between the causes of various health issues and aberrant protein O-GlcNAcylation.  
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It is believed that as researchers discover more about the specificity of the PTM and its 
direct roles, they will begin to unveil more insights into the causes of many disorders and 
diseases (Ma and Hart, 2014).  
1.3 O-GlcNAc in Human Health 
 As research continues to uncover the roles of O-GlcNAcylation on certain sites in 
specific proteins, a notable amount of attention has shifted towards looking at the role of 
this PTM on various diseases caused by metabolic dysfunctions.  Numerous epigenetic 
studies have led to the discovery that O-GlcNAc PTM functions in many important 
biological processes.  These functions include the role of O-GlcNAc in transcription 
(Gambetta et. al., 2009; Kelly & Hart, 1989), gene silencing (Yang et al., 2002), gene 
deletion in embryonic stem cells (Shafi et al., 2000), and cell cycle control.  Disruption of 
any of these functions may lead to aberrant proteins that could greatly affect human 
health (Vaidyanathan et al., 2014). 
 As described by Fehm and coworkers, the central nervous system (CNS) expends 
around half of all metabolized glucose (Fehm et al., 2006), suggesting that O-GlcNAc 
may occur in the brain.  Further studies indicated the ubiquitous neuronal presence of this 
PTM by discovering two presynaptic zone proteins to be some of the most substantially 
O-GlcNAc modified proteins ever observed (Trinidad et al., 2012).  The significant 
decrease of glucose metabolism in the brain that occurs with Alzheimer's disease has 
pointed attention toward the potential role of O-GlcNAcylation in that disease.  While 
changes in HBP flux and the enzymes of O-GlcNAc have been shown to impact the 
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disease (Liu et al., 2012), more research is needed to establish exactly how this PTM 
works to protect the brain and how a decline in this modification may be involved in the 
etiology of Alzheimer's disease.  Additionally, other critical CNS processes involving 
synaptic communication and memory development have established the importance of O-
GlcNAcylation on these processes (Vaidyanathan et al., 2014).  
 Another major biological process involving O-GlcNAc focuses attention on the 
effect of O-GlcNAc PTM in cardiac functioning.  Because O-GlcNAc functions as a 
stress response sensor, studies have found its importance in protection of the heart after a 
cardiac injury (Lima et al., 2009; Laczy et al., 2009).  The O-GlcNAc PTM further 
enhances cardiac protection through its role in cell signaling to defend against 
programmed cell death (apoptosis) and other cellular damage (Vaidyanathan et al., 2014). 
 While O-GlcNAcylation clearly plays a number of crucial roles in maintaining 
and protecting necessary bodily functions, the over-expression or under-expression of this 
modification and its enzymes may lead to serious issues.  As research continues, more is 
beginning to be understood about the role of O-GlcNAc PTM on health and disorders.   
1.4 O-GlcNAc in Cancer 
 Cancer research is a quickly evolving field in which new discoveries are 
consistently being made.  One major aspect of this research is a renewed focus on the 
energy metabolism of the cancer cells that allows them to survive, grow, and, in some 
cases, even spread to other places in the body.  The basis of unique cancer metabolism 
was first discovered by Otto Warburg, who found that cancer cells utilize glycolysis to 
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create energy despite being in a normal oxygenic environment.  Because glycolysis is a 
much less efficient energy-creating pathway, many researchers began looking into why 
cancer cells are able to thrive through this mechanism.  Although only relatively low 
levels of ATP are generated from glycolysis, large amounts of carbon and nitrogen can be 
absorbed from the byproducts of this pathway (e.g., lactate and ammonia).  Nearby 
cancer cells can use the absorption of such products as energy sources to increase their 
organic mass and facilitate the growth and spread of tumor cells (Ferrer et al., 2016). 
 Because the glycolytic pathway of cancer cells has been characterized, emerging 
studies examine the mechanisms through which the cells receive excess glucose to 
generate and maintain this metabolic pathway.  Because of the increased levels of 
glycolysis, increased flux must occur through pathways such as the hexosamine 
biosynthetic pathway and pentose phosphate pathway (PPP) to deliver the glucose needed 
for the tumor cells to survive.  The substrate UDP-GlcNAc is a product of the 
hexosamine biosynthetic pathway.  Therefore, increased levels of this product lead to 
increased O-GlcNAcylation of proteins, also known as hyper-O-GlcNAcylation.  This 
increased O-GlcNAc PTM has been found to occur ubiquitously in human cancers.   
 Because O-GlcNAc modification plays such a vital role in cancer metabolism, 
potential treatments may be able to target components of this PTM pathway.  Hyper-O-
GlcNAcylation of cancer cells suggests that OGT levels would also be increased in the 
cellular biosynthetic pathways.  Targeting the OGT enzyme through knockdown lowered 
the levels of O-GlcNAcylation which established contribution of this pathway to tumor 
growth (Ma and Voesseller 2014).  More specific studies were performed by Ferrer and 
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coworkers, where this group demonstrated that pharmacological inhibition of O-GlcNAc 
PTM reduced OGT levels and induced breast cancer cell apoptosis without affecting the 
localized non-cancerous epithelia (Ferrer et al., 2014).  This relationship between OGT 
levels and cancer cell viability has led to further study of its metabolic pathways and its 
interactions with O-GlcNAc in cancer.  Because O-GlcNAc plays such a wide variety of 
roles in biological processes, its effects on cancer cells can be readily tied to several 
hallmarks of cancer such as cell proliferation, survival, and metastasis (Ferrer et al., 
2016; Ma and Vosseller, 2014).   
 As O-GlcNAc has been found to play a role in cell cycle control, cancer cells are 
known to push cell cycle progression and skip vital checkpoints.  FoxM1, a regulator of 
cell cycle progression, is suggested to be sustained by O-GlcNAc PTM, but in oncogenes, 
this regulator is often over-expressed.  The cell cycle regulator, Cyclin D1, displays a 
similar pattern of expression.  Therefore, hyper-O-GlcNAcylation is correlated to the 
over-expression of both FoxM1 and Cyclin D1 which can cause the cell cycle to bypass 
necessary checkpoints, leading to excessive proliferation and tumor cell growth. 
 Another approach that oncogenic cells take to ensure their survival is the 
promotion of anti-apoptosis mechanisms.  Studies have indicated that O-GlcNAc plays a 
role in evading death.  Because O-GlcNAc PTM is a stress sensor, it is able to respond to 
many of the stresses that cancer cells must endure, such as a lack of nutrients, 
endoplasmic reticulum stress, and hypoxia.  While normal cells are typically unable to 
survive under these stressful environments, glycolytic mechanisms supported by O-
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GlcNAcylation are able to help tumor cells endure the stresses and avoid apoptosis (Ma 
and Vosseller, 2014). 
 More recent studies have begun to look at the potential role of O-GlcNAcylation 
in tumor cell metastasis (Ferrer et al., 2016; Ma and Vosseller, 2014).  Metastasis, the 
development of a secondary site of cancer cell growth, occurs because of the culmination 
of multiple processes.  One specific process is epithelial-mesenchymal transition (EMT), 
which is associated with cellular hypoxia and the loss of certain tumor suppressors.  The 
inhibition of OGT can actually reduce EMT and the metastasis of both breast and prostate 
cancer cells.  This outcome established a relationship between roles of both EMT and O-
GlcNAc in the tumor metastasis (Ferrer et al., 2016).  Research into the mechanistic 
details of how these processes work together and how O-GlcNAc functions with other 
processes is just beginning to yield exciting new findings (Ma & Vosseller, 2014). 
 The process of O-GlcNAcylation is a common PTM among cancers.  Therefore, 
strategies have emerged that target tumor cell hyper-O-GlcNAcylation with the aim to 
inhibit OGT to prevent excessive O-GlcNAc PTM.  This specific approach may become 
beneficial in developing therapies to treat malignant tumors.  Overall, O-GlcNAcylation 
research appears to have great promise in potential development of novel methods for 
treatment of cancer (Ferrer et al., 2016; Ma & Vosseller, 2014). 
1.5 O-GlcNAc and HIF 
 The process of O-GlcNAcylation has been found in numerous studies to 
reprogram metabolic pathways of cancer cells.  Hypoxia-inducible factor-1 (HIF-1) is a 
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transcriptional factor that mainly controls glycolytic enzymes, and thus may play some 
part in promoting the Warburg effect of cancer cells when increased O-GlcNAcylation 
occurs (Ma and Vosseller, 2014).  Specifically, one study found that reduction of O-
GlcNAcylation in cancer cells caused apoptosis of these cells and stress of their 
endoplasmic reticulum, which further caused degradation of HIF-1α protein.  This 
finding emphasized the regulation of glycolysis in cancerous cells through HIF-1α and 
the transcriptional target GLUT1.  Ferrer and his coworkers noted that breast cancer 
patients with high HIF-1α levels also have increased OGT and decreased OGA levels.  
These findings have been correlated with poorer outcomes for patients (Ferrer et al., 
2014; Ferrer et al., 2016).  
 Due to oncogenes, glutamine fructose-6-phosphate aminotransferase (GFAT), a 
rate-limiting enzyme in the HBP, has been found to have up-regulated levels in cancer 
cells.  These levels are related to an excessive uptake of glutamine that serve to drive the 
increased HBP flux so that the cancer cells can continue to receive the nutrients necessary 
to rapidly reproduce.  The GFAT expression increases the output of the hexosamine 
biosynthetic pathway, UDP-GlcNAc.  The transcription factor, HIF-1α, induces GFAT 
expression, which further shows its relation to O-GlcNAcylation (Ma and Vosseller, 
2014).    
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Chapter 2 
Post-translational O-GlcNAc Modification of Hypoxia-Inducible Factor (HIF) 
Proteins  
Dr. Yu-Dong Zhou, Dr. Dale G. Nagle, Hailey Grisham, Alexis Hill, and Sean Williamson 
2.1 Background and Introduction 
 Post translational O-GlcNAc modification (O-GlcNAcylation) plays a vital role in 
many metabolic pathways, including those implicated in a number of diseases.  
Abnormalities in this pathway have been connected with cancer pathogenesis.  In this 
study, T47D human breast cancer cells were tested through various experiments to 
investigate the effects of O-GlcNAc modification on hypoxia-inducible factor (HIF) 
proteins.  Cultured T47D cells were treated with 1,10-phenanthroline (an Fe++ chelator 
that activates HIF-1 in normoxic cells to induce a state of "chemical hypoxia") and 
PUGNAc (an inhibitor of O-GlcNAcase).  Nuclear and cytoplasmic extraction was 
performed and followed by protein concentration quantification.  Western blot analysis 
was first performed to determine the sensitivity of the extracted proteins to anti-HIF-1α 
and anti-HIF-2α antibodies, respectively.  Immunoprecipitation was subsequently 
performed with anti-HIF-1α and anti-HIF-2α antibodies as specified, followed by 
Western Blot to test the sensitivity of the precipitated proteins to an O-GlcNAc-specific 
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antibody.  A final re-blot was performed using anti-HIF-1α and anti-HIF-2α antibodies to 
confirm the presence of HIFα proteins in the immunoprecipitated samples. 
2.2 Materials and Methods 
2.2.1 Cell Culture and Compound Treatment  
 Human breast cancer T47D cells (ATCC) were derived from a metastatic site of 
human mammary glands.  Two million T47D cells were seeded into each well of a six-
well polystyrene tissue culture dish (CytoOne) in a volume of 2 mL of Dulbecco's 
Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12, Corning), supplemented 
with 10% fetal calf serum (FCS, Hyclone) and antibiotics (50 units/mL of penicillin and 
50 µg/mL of streptomycin, GIBCO).  The cells were cultured at 37°C overnight in a 
humidified environment under 5% CO2/95% air, treated with the following compound 
combinations: 1,10-phenanthroline (10 µM, Sigma) + O-(2-Acetamido-2-deoxy-D-
glucopyranosylidenamino) N-phenylcarbamate (PUGNAc, 30 µM, Sigma); 1,10-
phenanthroline (10 µM); PUGNAc (10 µM); or PUGNAc (30 µM) for 4 hours at 37°C.  
All compounds were purchased from Sigma, dissolved in DMSA, and the stock solutions 
stored at  −20°C. 
2.2.2 Nuclear and Cytoplasmic Extract Preparation 
 Following compound treatment, the cells were washed once with 1x Phosphate 
Buffered Saline (PBS), scraped to be detached, and the cell suspension transferred to a 
1.5 mL centrifuge, and the cell pellet collected by centrifugation at 500 x g for 5 minutes.  
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The pellet was washed twice with 1x PBS (two rounds of re-suspension and 
centrifugation).  The supernatant was removed, leaving a dry cell pellet.  Based on the 
packed cell volume of 10 µL, 100 µL of ice-cold cytoplasmic extraction reagent (CER I, 
Thermo Scientific) was added to the pellet.  To ensure the integrity of the proteins, a 
protease inhibitor cocktail (Sigma) was added to CER I and NER solutions at the 
manufacturer-recommended concentration. 
 The CER I and cell pellet mixture was vortexed at the highest setting of a bench-
top vortexer for 15 seconds to completely resuspend the pellet.  This mixture was 
incubated on ice for ten minutes before 5.5 µL of  CERII (Thermo Scientific) was added.  
After this addition, the tube was vortexed for five seconds and placed on ice for one 
minute.  After being vortexed one final time on the highest setting for five seconds, the 
mixture was centrifuged for five minutes in a refrigerated (4°C) in a micro-centrifuge at 
16,000x g.  The supernatant was immediately removed and transferred to a pre-chilled 
tube that was placed on ice.  The pellet, which is the insoluble portion that contains the 
nuclei, was suspended in 50 µL ice-cold nuclear extraction reagent (NER, Thermo 
Scientific).  The tube was vortexed on the highest setting for 15 seconds and placed on 
ice with an additional 15 seconds of vortex period every ten minutes for the entirety of 40 
minutes.  A final centrifugation of the tube at maximum speed for ten minutes was 
performed to obtain the supernatant (nuclear extract) portion to be transferred into a new 
pre-chilled tube and placed on ice to store in the freezer at −80°C until later use. 
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2.2.3 Protein Concentration Quantification 
 The Micro BCA Protein Assay Kit (Thermo Scientific) provided three micro BCA 
reagents (MA, MB, MC) and bovine serum albumin (BSA) standard ampules which 
contain 10 x 1 mL BSA at 2.0 mg/mL in a mixture of 0.9% saline and 0.05% sodium 
azide.  To prepare the BSA standards, different volumes of BSA standard and distilled 
water were divided into separate 5 mL tubes with micropipettes.  Table 2.1 below shows 
the exact volumes utilized in the experiment. 
Table 2.1 - BSA Standard Preparation
 The micro BCA working reagents (WR) were then prepared by mixing 25 parts 
Reagent MA (1750 µL) and 24 parts Reagent MB (1610 µL) with 1 part Reagent MC 
(140 µL).  Micropipettes were used to add 100 µL of each of the prepared standards into 
separate wells of a polystyrene 96-well microplate with an equal amount of the working 
Vial Volume of Diluent 
(µL)
Volume & Source of 
BSA (µL)
Final BSA 
Concentration (µg/
mL)
A 450 50 200
B 400 100 of vial A 40
C 510 90 of vial A 30
D 250 250 of vial B 20
E 250 250 of vial C 15
F 250 250 of vial D 10
G 250 250 of vial E 7.5
H 250 250 of vial F 5
I 250 250 of vial H 2.5
J 250 250 of vial I 1.25
K 250 0 0
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reagent added.  A plate shaker was used for 30 seconds to thoroughly mix the standards.  
The microplate was sealed and incubated at 37°C for one hour and then cooled to room 
temperature.  At this point, the absorbance was measured at 492/620 nm on a 
spectrophotometer using Magellan software.  The average absorption reading of the blank 
standard was subtracted from the absorbance reading of each of the individual standards.  
Microsoft Excel was used to prepare a standard curve by plotting the blank reading for 
each BSA standard versus its concentration to determine the protein concentration of each 
individual sample.  
2.2.4 Western Blot 
 To prepare the samples for SDS-PAGE gel electrophoresis, a sample buffer 
solution was prepared using 95 µL of 2x Laemmli sample buffer (Bio-Rad) with 5 µL of 
β-mercaptoethanol (BME, Sigma).  Protein quantification was performed to determine 
how much volume of the four NE and the four CE samples were necessary to get 15 µg 
of each sample to be mixed with the buffer solution.  The sample amounts utilized are 
displayed in Table 2.2 and were added to the USA Scientific's 1.5 mL tubes.  Following 
mixing within the pipette, 10.2 µL of the prepared buffer was added to each sample tube.  
The tubes were then placed in a hot water bath to boil for 5 minutes in order to denature 
the protein samples.  After boiling, the tubes were placed on ice. 
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    Table 2.2 - Protein Quantification
 To prepare the running buffer for SDS-PAGE gel electrophoresis, 20 mL of 
premade 10x Tris/Tricine/SDS buffer (Bio-Rad) were mixed and added to 180 mL of 
distilled deionized water (ddH2O, equivalent to a 1/10 dilution).  The denatured NER and 
CER samples were thawed, centrifuged, and placed on ice.  A Bio-Rad precast 4-20% 
gradient SDS-PAGE minigel was loaded with samples in the following order: molecular 
weight marker, NE1, NE2, NE3, NE4, CE1, CE2, CE3, CE4.  The gel was run at 100 
volts for an hour. 
 A 5x transfer buffer was prepared by dissolving 15.15 g of Tris Base and 72.1 g of 
glycine in 1 L ddH2O.  To obtain 1x transfer buffer, the following solutions were mixed in 
a beaker: 200 mL of 5x transfer buffer, 100 mL of methanol (Sigma), and 700 mL of 
ddH2O.  The gel was soaked in the transfer buffer and a transfer 'sandwich' that contains  
a black base, filter, filter paper, the gel, 45 µm nitrocellulose membrane, another filter 
paper, and a white base, was assembled under the surface of the transfer buffer.  The 
Sample Volume necessary 
for 15µg (µL)
NER (µL) CER (µL)
NE1 8.52 1.68 ----
NE2 8.93 1.27 ----
NE3 10.2 0 ----
NE4 8.2 2.00 ----
CE1 3.55 ---- 6.65
CE2 3.88 ---- 6.32
CE3 4.14 ---- 6.06
CE4 3.65 ---- 6.55
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electrotransfer was run at 140 milliamps for one hour on a stir plate.  Ponceau S solution 
(Sigma) was added to the membrane to ensure the transfer efficiency by staining the 
proteins. 
 To prepare the TTBS solution, 5 mL of 1M pH 6.8 Tris, 2.5 mL of 5M NaCl, and 
0.13 mL of Tween 20, were mixed with ddH2O to obtain a final volume of 125 mL.  The 
5% milk/TTBS solution was prepared by dissolving 5 grams of Blotting-Grade Blocker 
(nonfat dry milk, Bio-Rad) in 100 mL TTBS solution.  For blocking, the membrane was 
placed in the 5% milk/TTBS solution and incubated at 4°C overnight with gentle 
shaking. 
 The primary anti-HIF-2α polyclonal antibody (Novus) was added to the 
membrane in a 1:1000 dilution (10 µL of the antibody with 10 mL of the 5% milk/TTBS) 
for an hour at room temperature while rocking on a Boekel Scientific Rocker II.  The 
membrane was washed with 5% milk/TTBS for ten minutes while shaking and rocking, 
and then washed again with the same solution for five minutes while rocking.  The same 
steps utilized with the first antibody were followed with a secondary antibody of goat 
anti-rabbit IgG conjucated with horseradish peroxidase (HRP, Jackson Immunolab), that 
was prepared in a 1:3000 dilution (3.5 µL of the antibody in 10 mL).  The membrane was 
rocked for an hour and then washed once for ten minutes in TTBS and subsequently 
twice more for five minutes extra.  The extra liquid was drained and 1.5 mL of West 
Femto Max sensitivity substrate (Thermofisher) was added to the membrane to soak for 
five minutes before draining the excess liquid once again.  The membrane was placed in a 
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plastic membrane protector and placed in a Chemi Gel Doc (Bio-Rad) to perform 
chemiluminescence to acquire the Western Blot.   
2.2.5 Immunoprecipitation 
 In order to separate the protein of interest in T47D cells, Abcam's 
Immunoprecipitation protocol was followed.  One point five million T47D cells were 
cultured overnight in a 6 cm plate with 3 mL of 10% FCS, DMEM/F12, and P/S 
(penicillin and streptomycin).   The treatment conditions were: 1) media control, 2) 10 
µM 1,10-phenanthroline, 3) 30 µM PUGNAc, 4) 10 µM 1,10-phenanthroline plus 30 µM 
PUGNAc.  The NE and CE samples were prepared as described in the previous section, 
using the NE-CE isolation kit from ThermoFisher.  The protein concentrations were 
determined as described using the Micro BCA kit from ThermoFisher. 
 Over ice, the NE samples were divided into two sets of tubes for 
immunoprecipitation with anti-HIF-1α and anti-HIF-2α antibodies, respectively.  The 
solutions were separated into these tubes in the amounts listed in Table 2.3 below.  Then 
250 µg/µL of anti-HIF-1α, purified monoclonal antibody, and 1 mg/µL of anti-HIF-2α, 
purified polyclonal antibody, were added to the appropriate tubes.  The samples with the 
antibodies were incubated for four hours at 4°C under gentle rotation.  
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Table 2.3 - Isolation of Nuclear Extract 
 For the monoclonal anti-HIF-1α antibody, protein G-coupled Sepharose beads 
were used, while a protein A-coupled Sepharose beads were used for anti-HIF-2α 
polyclonal antibody.  Then 400 µL of beads were used and spun quickly to separate and 
remove the supernatant.  An equal volume of M-PER (Mammalian Protein Extraction 
Reagent, PIERCE) with 1x protease inhibitor cocktail (PI, Sigma) were added and mixed 
for an hour to create a slurry.  The slurry was then mixed and 55 µL of beads was added 
to each tube and kept on ice.  This lysate bead mixture was incubated at 4°C for five 
minutes and centrifuged at 3000 rpm (800 x g).  The supernatant was removed after the 
incubation and the beads were washed three times with 150 µL/tube of lysis buffer made 
up of a 9:1 mixture of  M-PER and 10x PI.  Each washing was followed with 
centrifugation for five minutes (first spin at 3000 rpm; second spin at 4000 rpm, third 
spin at 5000 rpm) at 4°C and removal of the supernatant. Once the last supernatant was 
removed, 35 µL/tube of 2x Laemmli buffer (loading buffer) was added.  The mixture was 
boiled at 94°C for 5 minutes to denature the protein and separate it from the beads.  The 
mixture was spun at 10000 rpm at 4°C for 5 minutes to retrieve the supernatant 
containing the protein.  This was placed in a new tube and stored at −20°C overnight. 
NE Wells Original Protein 
Concentration
1 1.76 14.2 µL ex / 2.8
2 1.68 14.9 µL ex / 2.1
3 1.47 17 µL ex
4 1.83 13.7 µL ex / 3.3
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2.2.6 O-GlcNAc Western Blot 
 To prepare the running buffer for gel electrophoresis, 20 mL of premade 10x Tris/ 
Tricine/SDS buffer (Bio-Rad) were mixed with 180 mL of ddH2O.  The already prepared 
tubes of immunoprecipitated NER samples were centrifuged and placed on ice.  The 
4-20% Mini-Protean TGX Precast Protein Gel (Bio-Rad) was loaded with the following: 
molecular weight marker, HIF-1α/NE1, HIF-1α/NE2, HIF-1α/NE3, HIF-1α/NE4, 
molecular weight marker, HIF-2α/NE1, HIF-2α/NE2, HIF-2α/NE3, HIF-2α/NE4.  The 
gel was run at 105 volts for an hour. 
 Western blot was performed as that described in the earlier section, using standard 
methods.  The primary antibody mouse anti-O-GlcNAc (CTD 110.6) monoclonal 
antibody (Cell Signaling Technology) was used at 1:1000 dilution 
2.2.7 Stripping of the Membrane and Reblot 
 The membrane was rinsed twice with TTBS and then immersed in Restore 
Western Blot Stripping Buffer (Thermofischer) at room temperature for 10 minutes with 
rocking.  The membrane was washed with TTBS three more times for five minutes each.  
It was then blocked in 5% milk/TTBS at room temperature with shaking for an hour.  The 
membrane was cut apart to separate the HIF-1α and the HIF-2α portions.  A primary 
antibody, rabbit anti-HIF-2α, is added to the HIF-2α portion of the membrane in a 1:1000 
dilution (10 µL in 10 mL).  Similarly, a primary mouse anti-HIF-1α antibody was added 
to the HIF-1α portion of the membrane in an identical dilution.  Both of these additions 
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were left overnight on the membrane at 4°C with rocking.  The membrane was washed 
with secondary antibody and blocked with 5% milk/TTBS.  The extra liquid was drained 
and 1.5 mL of West Femto Max sensitivity substrate was added to the membrane to soak 
for five minutes at room temperature before draining the excess liquid once again.  The 
membrane was placed in a plastic membrane protector and placed in a Chemi-Gel Doc 
(Bio-Rad) to perform chemiluminescence to obtain the images. 
2.3 Results 
Figure 2.1: Experimental Flow Chart 
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 Figure 2.1 displays an overview of the procedural steps taken to complete this 
experiment.  It highlights specific portions of the process that have graphs and data 
displayed in this section of results.  
Figure 2.2: Standard Curve for Protein Concentration Determination 
 A spectrophotometer using Magellan software was used to measure the 
concentration of proteins present in the T47D cell culture samples.  The average 
absorption reading of the blank standard was subtracted from the absorbance reading of 
each of the individual standards.  This standard curve was prepared using Microsoft 
Excel by plotting the blank reading for each BSA standard versus its concentration to 
determine the protein concentration of each individual sample. The equation y = 0.014x + 
0.14 was obtained from the slope of the line, so that the absorbance values can be 
plugged into the x value to determine the y value that represents protein concentration.  
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Figure 2.3: Western Blot for HIF-2α Proteins in T47D cells 
 
  
 This Western Blot displays varying treatments on T47D cells.  The marks on the 
blot in the order from left to right display: media control, 1,10-phenanthroline, PUGNAc, 
and 1,10-phenanthroline with PUGNAc.  The bands on the blot confirm that proteins are 
present and that the antibody (HIF-2α in this figure) was able to detect to the proteins of 
interest.  The signals were stronger for the cells treated with 1,10-phenanthroline and 
those treated with 1,10-phenanthroline + PUGNAc.  
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Figure 4: Western Blot for O-GlcNAc  
 
 This Western Blot displays the effects of the O-GlcNAc antibody on the varying 
nuclear extract treatments (the samples were loaded in the same order as that in Figure 
2.3).  This result shows that the antibody did, in fact, detect the presence of O-GlcNAc 
modification in the proteins of interest (HIF-1α protein), in the presence of OGA inhibitor 
PUGNAc.  Similar results were obtained for HIF-2α protein. 
   23
m
ed
ia 
co
nt
ro
l 
1,
10
-p
he
na
nt
hr
oli
ne
 
PU
GN
Ac
 
1,
10
-p
he
na
nt
hr
oli
ne
 w
ith
 P
UG
NA
c
104 kD
Figure 5: Western Blot for HIF-1α and HIF-2α 
 
 
 
 
 This set of Western Blots confirms that O-GlcNAc post translational modification 
occurs through hypoxia-inducible factor (HIF-1α and HIF-2α) proteins of T47D breast 
cancer cells.  The subjection of this pathway onto these proteins is displayed by the bands 
shown on the blot. 
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2.4 Conclusion and Discussion 
 The extent of O-GlcNAc post translational modification functioning continues to 
be uncovered as researchers are discovering new methods of site-mapping specific O-
GlcNAc proteins and new methods to profile these proteins.  Research has shown its 
etiological influence in a vast range of diseases including: cardiac injuries, diabetes, 
Alzheimer's, and cancer.  One common feature of the role of O-GlcNAc in these disease 
processes is its control at either or both the cell cycle and transcriptional level.  Although 
these findings display great progress, further research is needed to define the role O-
GlcNAc modification plays in specific proteins (Vaidyanathan et al, 2014). 
 Because hyper-O-GlcNAcylation has been correlated to the over-expression of 
several cell cycle regulators that cause the cell cycle to bypass necessary checkpoints, 
researchers believe that it leads to excessive proliferation and tumor cell growth.  Further 
pursuit of this research is necessary to determine which proteins are subjected to O-
GlcNAc PTM so that they can be specifically targeted therapeutically.  Additionally, the 
process of O-GlcNAcylation has been found in numerous studies to reprogram the 
metabolic cancer cell pathways.  Hypoxia-inducible factor (HIF) is a transcriptional 
factor protein that mainly controls glycolytic enzymes, and plays an important role in 
promoting the Warburg effect of cancer cells when increased O-GlcNAcylation occurs 
(Ma and Vosseller, 2014).  The connection between the O-GlcNAc PTM and HIF proteins 
highlights an area of research to be further studied. 
 This particular study focused on the potential of O-GlcNAcylation on HIF 
proteins in T47D breast cancer cells.  After the series of experiments, it was concluded 
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that the antibodies did, in fact, detect the presence of O-GlcNAc modification in the 
proteins of interest (HIF-1α and HIF- α proteins), in the presence of OGA inhibitor 
PUGNAc.  Further research is needed to decipher the direct role of O-GlcNAc in these 
HIF proteins and to determine how the PTM effects the metastasis of the tumor cells.  
The study of O-GlcNAcylation and its roles in biological process is a quickly evolving 
process.  As more efficient tools and methods of site-mapping are developed, a deeper 
clarification of the O-GlcNAc pathway and its specific roles will be possible (Ma and 
Hart, 2014).  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